Developing the first class of ADCs based on NMT inhibition
Myricx Bio is a UK biotech company focused on discovering and developing a novel class of payloads for antibody drug conjugates (ADCs) based on inhibitors of N-myristoyltransferases (NMT) for the treatment of cancer. Founded on world-leading NMT biology and chemistry research, Myricx is advancing a pipeline of NMTi-ADC programs against validated oncology targets including B7-H3 and HER2 toward clinical development.
Create a free account to see funding visualizations and detailed round data.
Create Free AccountJul 2024
Create a free account to see which investors have funded this company.
Create Free Account
Developer of engineered cells as medicines to treat diseases by repairing or replacing cells for ...
China's leading mRNA biotech company developing therapeutics for cancer and infectious diseases.
Biopharmaceutical company developing and commercializing RNAi therapeutics to treat genetically d...
Clinical-stage programmable cell therapy company developing engineered T-cell therapies for solid...
Clinical-stage biotechnology company developing T-cell engager therapeutics for autoimmune and in...
Develops Gene Writing technology and non-viral delivery to create in vivo genetic medicines for m...
